ALKERMES, INC.
🇺🇸United States
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 623
- Registration Number
- NCT01469039
- Locations
- 🇺🇦
Alkermes Investigational Site, Vinnytsya, Ukraine
🇺🇸Alkermes Investigational site, Leesburg, Florida, United States
A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01453374
- Locations
- 🇺🇸
Friends Research Institute, Baltimore, Maryland, United States
Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery
Phase 3
Terminated
- Conditions
- Laparoscopic Surgery
- Interventions
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01436032
- Locations
- 🇺🇸
Lotus Clinical Research LLC, Pasadena, California, United States
ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry
Completed
- Conditions
- Opioid Dependence
- First Posted Date
- 2011-08-24
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT01422837
- Locations
- 🇺🇸
Innovation Laboratory/PEARL, Johnson City, Tennessee, United States
🇺🇸Arkansas Psychiatric Clinc, Little Rock, Arkansas, United States
🇺🇸Psychotherapy Services, Etc., Groton, Connecticut, United States
ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT01418092
- Locations
- 🇺🇸
Alkermes Investigational Site, Bellevue, Washington, United States
ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT01382797
- Locations
- 🇺🇸
Alkermes Study Site, San Antonio, Texas, United States
🇺🇸Alkermes Investigational Site, De Land, Florida, United States
ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2011-08-23
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01381107
- Locations
- 🇺🇸
Comprehensive NeuroScience, Inc., Atlanta, Georgia, United States
ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT01366001
- Locations
- 🇺🇸
Alkermes Study Site, Overland Park, Kansas, United States
ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults
Phase 3
Completed
- Conditions
- Alcoholism
- Interventions
- Drug: Placebo matching Medisorb naltrexone 190 mgDrug: Placebo matching Medisorb naltrexone 380 mgDrug: Medisorb naltrexone 190 mg
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 624
- Registration Number
- NCT01218958
ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)
Phase 3
Completed
- Conditions
- Alcohol Dependence
- Interventions
- Drug: Medisorb naltrexone 190 mg
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2010-12-24
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT01218971
© Copyright 2025. All Rights Reserved by MedPath